Knowledge HQ

Reviews improvements to TIL manufacturing. Implementing G-Rex 100MCS devices for the Rapid Expansion Protocol (REP) reduced technical interventions, media usage, and contamination risk while maintaining comparable tumor specificity to flask/bag methods.

A scalable protocol for producing red blood cells from adult PBMCs was developed. The G-Rex allowed for massive expansion (3x10^6 fold) of erythroblasts and supported efficient differentiation and enucleation, comparable to standard culture dishes.

Developed "universal" CAR T cells using a lentiviral vector coupling CAR expression with CRISPR/Cas9 gene editing. G-Rex were used for conventional control cultures to compare against the automated CliniMACS Prodigy system.

Prospective analysis of TIL therapy in metastatic melanoma. The Rapid Expansion Protocol (REP) was performed using G-Rex 100M, contributing to the generation of infusion products. High TIL numbers were associated with response.

Review comparing cell culture systems (bags vs flasks) for dendritic cell production. Discusses gas permeability and materials. References Wilson Wolf patents related to gas-permeable devices as examples of improved culture methods utilizing silicone rubber membranes.

Investigated methods to overcome fratricide in NKG2D-CAR T cell production. The manufacturing process included an expansion phase in G-Rex containers, which was part of the upscaling strategy to produce sufficient cell yields.

Generated MUC1-specific CAR T cells co-expressing an inverted cytokine receptor (4/7ICR) for breast cancer. Co-culture experiments to monitor anti-tumor activity were conducted in 6-well G-Rex devices using a 3D algimatrix bioscaffold.

Evaluated Lym-1 CAR T cells against B-cell lymphoma. Primary T cells were transduced and expanded in 24-well G-Rex plates. The cells showed potent anti-tumor effects in vitro and in vivo against Raji xenografts.

Study on 4-1BB agonist enhancing CD8+ TIL growth from pancreatic ductal adenocarcinoma (PDAC). The Rapid Expansion Protocol (REP) was performed in G-Rex 10 devices, enabling the exponential growth of sorted CD8+ and bulk TIL populations for functional assays.

Describes Iovance's Gen 2 manufacturing process for LN-144 (TILs), an abbreviated 22-day closed process yielding cryopreserved product. The Gen 2 process uses a single closed bioreactor to improve scalability and throughput compared to the Gen 1 method.

Describes a culture method using GM-CSF, TLR agonists, and IL-7 to expand antigen-specific T-cells from PBMC. The study confirmed the culture method could be scaled up using G-Rex 100M vessels, showing effectiveness comparable to 24-well plates for patient treatment.

Investigates mesothelin as an immunotherapeutic target in glioblastoma. Mesothelin-specific T-cell responses were detected in TILs. G-Rex were utilized for the further expansion of TILs isolated from glioma tumor tissue to achieve necessary cell numbers.